BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

PALO ALTO, Calif., May 6, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 11 AM (ET). The presentation will be webcast live and can be accessed at www.bridgebio.com on the For Investors page under News & Events. The webcast will […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., April 3, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 31, 2020, the compensation committee of BridgeBio’s board of directors granted six employees options to purchase an aggregate of 52,916 shares of the Company’s common stock with a per share […]

BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or Metastatic Solid Tumors with FGFR Genetic Alterations SAN FRANCISCO – March 12, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics announced today that patients […]

BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

PALO ALTO, Calif., March 4, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, March 3, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 2, 2020, the compensation committee of BridgeBio’s board of directors granted two new employees options to purchase an aggregate of 5,812 shares of the Company’s common stock with a per […]

BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board Of Directors

President of Johns Hopkins University joins BridgeBio to expand and deepen partnerships with academia PALO ALTO, Calif. – February 24, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Ronald J. Daniels, president of Johns Hopkins University, to its board of directors, effective immediately. “We […]

BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

PALO ALTO, Calif., February 21, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are presenting at two upcoming investor conferences: The SVB Leerink Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 1PM (EST) in New York. The Cowen and Company Annual Health […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, CA, February 5, 2020 — BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 3, 2020, the compensation committee of BridgeBio’s board of directors granted nine new employees options to purchase an aggregate of 96,361 shares of the Company’s common stock with a per […]

BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

The deal is designed to accelerate BridgeBio’s gene therapy programs The dedicated suite will support clinical and commercial supply needs for BridgeBio’s gene therapy programs for congenital adrenal hyperplasia (BBP-631) and Canavan disease (BBP-812) PALO ALTO, Calif. – January 10, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration agreement with Catalent to […]

PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People with High Frequency Basal Cell Carcinoma

SAN FRANCISCO – January 8, 2020 – PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High-Frequency Basal Cell Carcinoma (HF-BCC). HF-BCC is a rare disease that causes a […]